Tigecycline

Active pharmaceutical substance formulated in Jan Aushadhi generic products for Antibiotics & Anti-Infectives treatment.

🧴 Clinical Application

Administered exclusively in hospital/ICU settings via slow intravenous infusion over 30 to 60 minutes after reconstitution and dilution in 0.9% Normal Saline or 5% Dextrose. Initial loading dose of 100 mg followed by 50 mg every 12 hours.

⚠️ Side Effects

Common: Severe nausea and vomiting (up to 30% of patients), diarrhea, headache, abdominal pain. Rare/Severe: FDA Boxed Warning: Increased risk of all-cause mortality; acute pancreatitis, severe hepatic cholestasis/failure, and pseudotumor cerebri.

🛡️ Safety Warnings

FDA Boxed Warning: Tigecycline is associated with an increase in all-cause mortality compared to comparator treatments; reserve for situations where alternative treatments are not suitable. Avoid in patients with severe hepatic impairment without dose adjustment. High risk of treatment failure in bacteremia/pneumonia due to low serum concentrations.